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Recently, we found that greater norepinephrine transporter (NET) availability in the locus 
coeruleus of trauma survivors with posttraumatic stress disorder (PTSD) was associated with 
increased severity of anxious arousal (i.e., hypervigilance and exaggerated startle) 
symptoms, but not any of the other empirically-derived symptom clusters that characterize 
this disorder.1 This finding suggests that greater NET availability in the locus coeruleus may 
serve a compensatory function of clearing elevated synaptic norepinephrine and maintaining 
anxious arousal symptoms in persons with PTSD.
A single nucleotide polymorphism (SNP) found in the promoter region of the NET gene 
SLC6A2 (rs2242446) has been associated with panic disorder.2,3 Given similarities in the 
clinical presentation of panic disorder and anxious arousal symptoms of PTSD,4 and data 
linking NET availability in the locus coeruleus to anxious arousal,1 it is reasonable to 
hypothesize that this SNP might be linked to anxious arousal in trauma survivors. We 
evaluated this possibility using data from the Detroit Neighborhood Health Study (DNHS), 
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an epidemiologic study of trauma-related psychopathology in a representative sample of 
predominantly African-American adults from urban Detroit.5
Methods
Data were analyzed from 580 participants who provided information regarding trauma 
exposure and PTSD, and had valid data for rs2242446 from blood or saliva samples.5 
Although some additional SNPs have been significantly associated with panic disorder in 
prior studies,2,3 only rs2242446 was genotyped in the DNHS; thus, we focused on this SNP. 
The DNHS was approved by the University of Michigan Institutional Review Board, and all 
participants provided written informed consent.
PTSD symptom dimension scores from the PTSD Checklist (PCL) were computed by: 1) 
summing item responses to create scale scores for each symptom cluster, and 2) counting the 
number of symptoms endorsed at a “moderate” or greater level for each symptom cluster. 
Linear regressions predicting scores on the five PTSD symptom dimensions were conducted 
using Plink version 1.07,6 with age, sex, and number of traumatic event types entered as 
covariates; the first two principal components from a multidimensional scaling analysis of 
genome-wide data were additionally included as covariates to adjust for population 
stratification. Alpha was set to .01 to reduce the likelihood of Type I error when testing 
associations between number of minor (G) alleles and the different symptom dimensions.
Results
Table 1 shows sample characteristics and results of regression analyses, which revealed that 
rs2242446 genotype, coded additively as the number of minor (G) alleles, significantly 
predicted both scale scores and count of anxious arousal symptoms but none of the other 
symptom clusters or severity or probable diagnosis of PTSD. Participants with two G alleles 
reported the highest level of anxious arousal symptoms (Mscale score=5.27; Mcount=1.00), 
followed by those with one G allele (Mscale score=4.74; Mcount=0.81), and those with zero G 
alleles (Mscale score=4.58; Mcount=0.73). No significant interactions between rs2242446 
genotype and the number of traumatic event types emerged for either anxious arousal 
outcome, all βs<0.17, all ps>.01.
Discussion
These results build on our prior finding that greater NET availability in the locus coeruleus 
is linked to increased anxious arousal1 and previous studies linking SNPs in SLC6A2 to 
panic disorder2,3 to suggest an independent association between a polymorphism in the 
promoter region of SLC6A2 (rs2242446) and anxious arousal symptoms of PTSD. The 
magnitude of this association ranged from small-to-moderate based on the number of risk 
alleles.7 Given that the SLC6A2 gene encodes for the NET, this polymorphism may affect 
NET synthesis, which in turn modulates anxious arousal symptoms in trauma survivors. 
This association was especially pronounced for exaggerated startle response, which suggests 
a role for this SNP in modulating panic-based hyperreactivity4 in trauma survivors. 
Importantly, that this association was not significant for any other symptom cluster or for 
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total severity or probable diagnosis of PTSD, underscores the importance of evaluating how 
candidate genetic markers for PTSD are linked to symptom clusters that comprise this 
phenotype.
This study demonstrates the utility of a translational epidemiologic approach to 
characterizing genetic correlates of psychiatric phenotypes, as it uses the best available, 
empirically-derived information regarding the phenotypic expression of PTSD4 and attempts 
to link candidate genetic polymorphisms to component aspects of this complex phenotype. 
Further research will be useful in replicating these results, assessing how other genetic 
markers may be linked to the phenotypic expression of PTSD, and evaluating the utility of 
genotyping for risk genes associated with PTSD in personalizing treatment approaches for 
symptomatic trauma survivors.
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Table 1
Sample characteristics and results of regression analyses examining associations between SLC6A2 rs2242446 
genotype and PTSD symptom dimensions
Sample characteristics
M (SD), n (%), or
proportion
Range in Sample
Age 52.4 (16.0) 18-90
Female sex 329 (56.7%) -
Race -
 African-American 480 (82.8%) -
 White 65 (11.2%) -





Genotype frequency Hardy-Weinberg equilibrium, p>.99
 A/A 371 (64.0%) -
 A/G 186 (32.0%) -
 G/G 23 (4.0%) -
Results of Regression Analyses
Descriptive statistics Regression results
M (SD) or
n (%)
Range β t p
PTSD Symptoms
PCL total severity 35.50 (15.60) 17-85 0.04 1.16 .25
 Re-experiencing 11.26 (5.16) 3-25 0.01 0.17 .87
 Avoidance 4.36 (2.59) 1-10 0.04 1.04 .30
 Numbing 9.28 (4.89) 4-25 0.02 0.45 .65
 Dysphoric Arousal 5.86 (3.43) 2-15 0.06 1.69 .09
 Anxious Arousal 4.66 (2.48) 2-10 0.09 2.45 .01
Counts of Symptoms
 Re-experiencing 1.80 (1.68) 0-5 −0.00 0.01 .99
 Avoidance 0.68 (0.84) 0-2 0.03 0.86 .39
 Numbing 1.21 (1.55) 0-5 0.01 0.29 .78
 Dysphoric Arousal 0.80 (1.10) 0-3 0.05 1.36 .17
 Anxious Arousal 0.76 (0.80) 0-2 0.12 3.04 .002
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Results of Regression Analyses
Descriptive statistics Regression results
M (SD) or
n (%)
Range β t p
Endorsement of Anxious Arousal Symptoms OR (95% CI) t p
 Hypervigilance 283 (48.8%) 0-1 1.41 (1.03, 1.95) 2.12 .03
 Exaggerated Startle 160 (27.6%) 0-1 1.76 (1.25, 2.49) 3.24 .001
OR (95% CI) t p
Probable PTSD 92 (15.9%) − 0.97 (0.65, 1.44) 0.17 .86
rs2242446 genotype was entered as the number of minor (G) alleles.
Greater trauma exposure was significantly associated with higher symptom levels for all symptom dimensions (all βs>0.28, all ps<.01), and female 
sex was significantly associated with higher re-experiencing, dysphoric arousal, and anxious arousal (scale score only) symptoms (all βs>0.12, all 
ps<.01). The first principal component was significantly associated with anxious arousal (scale score only; β=0.16, p<.0001) and avoidance 
(βs=0.12, p's<.01) symptoms. No significant interactions between the number of traumatic events and rs2242446 genotype emerged for either 
anxious arousal outcome, all βs<0.17, all ps>.01.
OR=odds ratio; 95% CI=95% confidence interval.
Re-experiencing symptoms=DSM-IV B1-B5 symptoms; Avoidance symptoms=C1-C2 symptoms; Numbing symptoms=C3-C7 symptoms; 
Dysphoric arousal=D1-D3 symptoms; Anxious arousal=D4-D5 symptoms.4 Formal confirmatory factor analyses in the DNHS sample revealed 
that the 5-factor model of PTSD symptoms provided the best fit to PCL data (data not shown, available from first author).
aAll regression models included sex, age, number of lifetime traumatic events, and the first two principal components from a multidimensional 
scaling analysis of genomewide markers as covariates.
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